| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
25,020 |
16,504 |
$4.73M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
15,427 |
9,885 |
$4.41M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
9,904 |
7,178 |
$831K |
| 80053 |
Comprehensive metabolic panel |
15,339 |
12,797 |
$383K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
16,164 |
13,311 |
$339K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
712 |
509 |
$245K |
| 36415 |
Collection of venous blood by venipuncture |
24,040 |
20,140 |
$195K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,697 |
2,267 |
$176K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,639 |
1,452 |
$132K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,249 |
2,849 |
$122K |
| 81514 |
|
294 |
253 |
$85K |
| 81001 |
|
5,153 |
4,489 |
$78K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
942 |
873 |
$65K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
735 |
614 |
$45K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,393 |
1,298 |
$40K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,248 |
1,127 |
$37K |
| 84484 |
|
1,163 |
932 |
$36K |
| 71045 |
Radiologic examination, chest; single view |
431 |
360 |
$29K |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
3,262 |
2,335 |
$28K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
412 |
391 |
$24K |
| 80061 |
Lipid panel |
1,035 |
934 |
$24K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
3,534 |
2,864 |
$18K |
| 85610 |
|
1,343 |
1,156 |
$18K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
940 |
859 |
$17K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
843 |
501 |
$16K |
| 83690 |
|
655 |
580 |
$15K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
262 |
237 |
$15K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
262 |
237 |
$15K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
346 |
331 |
$13K |
| 83605 |
|
618 |
521 |
$13K |
| 83735 |
|
802 |
698 |
$12K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
346 |
224 |
$7K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
40 |
37 |
$6K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
12 |
12 |
$4K |
| 71046 |
Radiologic examination, chest; 2 views |
27 |
27 |
$4K |
| 88142 |
|
87 |
81 |
$4K |
| 80306 |
|
57 |
51 |
$3K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
132 |
112 |
$3K |
| 83880 |
|
49 |
38 |
$3K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
31 |
31 |
$3K |
| 99233 |
Prolong inpt eval add15 m |
87 |
49 |
$3K |
| 85730 |
|
146 |
124 |
$2K |
| 85027 |
|
204 |
168 |
$2K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
18 |
12 |
$2K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
80 |
73 |
$2K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
70 |
59 |
$2K |
| 96367 |
|
46 |
24 |
$2K |
| J3490 |
Unclassified drugs |
77 |
27 |
$1K |
| A9270 |
Non-covered item or service |
1,414 |
1,127 |
$1K |
| 87800 |
|
45 |
40 |
$1K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
13 |
12 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
53 |
49 |
$1K |
| 82607 |
|
33 |
29 |
$988.67 |
| 0001A |
|
36 |
32 |
$919.20 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
14 |
12 |
$882.00 |
| 82803 |
|
21 |
15 |
$826.14 |
| 82746 |
|
12 |
12 |
$705.60 |
| 0011A |
|
22 |
20 |
$638.40 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
17 |
13 |
$577.00 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
30 |
30 |
$540.96 |
| 91300 |
|
36 |
32 |
$0.00 |
| 91301 |
|
22 |
20 |
$0.00 |